Joachim Neumann il 20/09/2026

Contractile effects of Aficamten in the human atrium

Naunyn Schmiedebergs Arch Pharmacol. 2026 Sep 21. doi: 10.1007/s00210-026-05924-3. Online ahead of print.ABSTRACTAficamten is an approved drug to treat hypertrophic cardiomyopathy. Aficamten desensitizes bovine myofilaments against calcium cations. In isolated animal cardiac preparations, aficamten

A J Marian il 19/09/2026

Hypertrophic Cardiomyopathy is a Disease of Sarcomere Proteins

Methodist Debakey Cardiovasc J. 2026 Sep 15;22(4):51-67. doi: 10.14797/mdcvj.1900. eCollection 2026.ABSTRACTHypertrophic cardiomyopathy (HCM) is a primary disease of cardiac myocytes caused by mutations in genes encoding sarcomere proteins. The ensuing phenotype, however, is multicellular, induced b

Frans Serpa il 16/09/2026

Electrocardiographic and Arrhythmic Manifestations of End-Stage Atrial Myopathy in Patients With Longstanding Persistent or Permanent Atrial Fibrillation: A 3-Patient Case Series

Am J Case Rep. 2026 Sep 16;27:e953661. doi: 10.12659/AJCR.953661.ABSTRACTBACKGROUND Advanced atrial remodeling, often associated with atrial fibrosis, may be accompanied by severe atrial electrical dysfunction and a range of electrocardiographic and arrhythmic manifestations. Data on the clinical fe